cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Atara Biotherapeutics Inc
6 own
23 watching
Current Price
$13.03
$0.52
(4.16%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
81.99M
52-Week High
52-Week High
39.50000
52-Week Low
52-Week Low
6.50000
Average Volume
Average Volume
0.06M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization81.99M
icon52-Week High39.50000
icon52-Week Low6.50000
iconAverage Volume0.06M
iconDividend Yield--
iconP/E Ratio--
What does the Atara Biotherapeutics Inc do?
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Read More
How much money does Atara Biotherapeutics Inc make?
News & Events about Atara Biotherapeutics Inc.
Business Wire
1 year ago
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced that Carol Gallagher will assume the role of Chair of the Board of Directors, replacing Ron Renaud, who is stepping down to focus on his new position as Managing Director at Bain Capital Life Sciences. Since 2020, I have had the privilege...
Business Wire
1 year ago
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced updated interim analysis and safety results...
Business Wire
2years ago
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief...
Benzinga
2years ago
Atara Biotherapeutics (NASDAQ:ATRA) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that Atara Biotherapeutics will report an earnings per share (EPS) of $-0.78. read more...
Business Wire
2years ago
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced new magnetic resonance imaging (MRI) biomarker...
Frequently Asked Questions
Frequently Asked Questions
What is Atara Biotherapeutics Inc share price today?
plus_minus_icon
Can Indians buy Atara Biotherapeutics Inc shares?
plus_minus_icon
How can I buy Atara Biotherapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Atara Biotherapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Atara Biotherapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Atara Biotherapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Atara Biotherapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Atara Biotherapeutics Inc?
plus_minus_icon
What percentage is Atara Biotherapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Atara Biotherapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$13.03
$0.52
(4.16%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
CEL-SCI Corp
CEL-SCI Corp
$0.49
$-0.07 (-11.66 %)
AFFIMED NV
AFFIMED NV
$2.33
$0.01 (0.43 %)
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
$0.77
$-0.03 (-3.49 %)
ORAMED PHARMACEUTICALS INC
ORAMED PHARMACEUTICALS INC
$2.40
$-0.12 (-4.58 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
CEL-SCI Corp
CEL-SCI Corp
$0.49
$-0.07 (-11.66 %)
AFFIMED NV
AFFIMED NV
$2.33
$0.01 (0.43 %)
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
$0.77
$-0.03 (-3.49 %)
ORAMED PHARMACEUTICALS INC
ORAMED PHARMACEUTICALS INC
$2.40
$-0.12 (-4.58 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00